Anne Aries

87 Avenue D'Altkirch
Mulhouse, 68100, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Liquid Biopsy and Epigenetic Signatures in AML, ALL, and CNS Tumors: Diagnostic and Monitoring Perspectives.

Liquid Biopsy and Epigenetic Signatures in AML, ALL, and CNS Tumors: Diagnostic and Monitoring Perspectives.

Journal: International journal of molecular sciences

Published: June 12, 2025

Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.

Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.

Journal: International journal of molecular sciences

Published: October 31, 2023

Development of a potency assay for CD34+ cell-based therapy.

Development of a potency assay for CD34+ cell-based therapy.

Journal: Scientific reports

Published: June 06, 2023

Deciphering the Cardiovascular Potential of Human CD34+ Stem Cells.

Deciphering the Cardiovascular Potential of Human CD34+ Stem Cells.

Journal: International journal of molecular sciences

Published: April 26, 2023

Industrialized GMP Production of CD34+ Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe.

Industrialized GMP Production of CD34+ Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe.

Journal: Stem cell reviews and reports

Published: April 03, 2022

Differential Expression of the Tetraspanin CD9 in Normal and Leukemic Stem Cells.

Differential Expression of the Tetraspanin CD9 in Normal and Leukemic Stem Cells.

Journal: Biology

Published: March 01, 2021

VSELs Maintain their Pluripotency and Competence to Differentiate after Enhanced Ex Vivo Expansion.

VSELs Maintain their Pluripotency and Competence to Differentiate after Enhanced Ex Vivo Expansion.

Journal: Stem cell reviews and reports

Published: May 08, 2018

Design and Validation of an Automated Process for the Expansion of Peripheral Blood-Derived CD34+ Cells for Clinical Use After Myocardial Infarction.

Design and Validation of an Automated Process for the Expansion of Peripheral Blood-Derived CD34+ Cells for Clinical Use After Myocardial Infarction.

Journal: Stem cells translational medicine

Published: December 04, 2017

Showing 1-8 of 8

Last Updated: 09/26/2026